FDA SAMD Clinical Evaluation Final Guidance

On Dec. 8, 2017, the FDA released the final guidance, “Software as a Medical Device (SAMD): Clinical Evaluation.” The October 14, 2016, draft is now obsolete. This guidance is actually the use of an International Medical Device Regulators Forum (IMDRF) document completed in June of 2017, so this represents broad international consensus. This guidance discusses various types of clinical evidence to support safety and effectiveness of a wide range of software devices. Information is provided on the FDA’s perspective on use of pre-existing scientific and clinical information, analytical evaluation, and bench testing. It also distinguishes between expectations for well-established clinical associations vs. novel clinical associations. Section 9.0 discusses Continuous Leveraging of Real World Performance Data to support additional performance claims and functions or to reduce such claims. The full guidance is at the link provided. PDF Copy of FDA Guidance

Schedule Discussion with John F. Murray, Jr.

John is currently providing telephone and face-to-face meetings to discuss:  Cybersecurity, Part 11, 483 Response, design controls expectations for software documentation, and other topics.

Leave a message and we will contact you to schedule:

Corporate Office

+1-781-721-2921
Partners located in the US (CA, FL, MA, MN, TN) and Italy.